Quantcast

Latest Orphan drugs Stories

2011-09-21 16:45:00

Dr Lise Aagaard has been appointed Editor-in-Chief of the new open access journal Orphan Drugs: Research and Reviews, published by Dove Medical Press Auckland, New Zealand (PRWEB) September 21, 2011 Dove Medical Press has announced the appointment of Dr Lise Aagaard as the Editor-in-Chief of the new journal Orphan Drugs: Research and Reviews. This international, peer-reviewed, open access journal will publish original research, reports, reviews and commentaries on all areas of the design...

2011-07-18 15:44:58

Studies Provide Insight to the Oncology Community on New Treatments, Methods to Predict Best Outcomes, and Patient Quality of Life Issues Researchers from the John Theurer Cancer Center at Hackensack University Medical Center presented results from 14 cancer-related studies during the recently concluded American Society of Clinical Oncology (ASCO) Annual Meeting, which took place June 3 "“ 7, 2011 in Chicago. The studies examined new cancer treatments, ways to predict the best treatment...

2011-07-01 06:54:20

(Ivanhoe Newswire) "“ A new study reveals that cancer patients treated with the drugs sunitinib and sorafenib responded to the flu vaccine, which suggests the agents do not damage the immune system as much as previously feared. "The damage that chemotherapy does to normal, healthy cells as it treats cancer has been well documented, but the precise effect that the new class of targeted agents has on the immune system is less well known. This study helps us answer that question," Keith...

2011-06-30 09:00:00

MEMPHIS, Tenn., June 30, 2011 /PRNewswire-USNewswire/ -- Accelerated Community Oncology Research Network, Inc., (ACORN), reported positive results of a large double-blind, randomized Phase 2b trial in patients with breast cancer at the American Society of Clinical Oncology (ASCO) 47th annual meeting in Chicago, June 3-7. The study, managed by ACORN Research, evaluated a novel drug regimen for the treatment of locally advanced or metastatic breast cancer. The regimen,...

2011-06-07 07:00:00

SOUTH SAN FRANCISCO, Calif., June 7, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the presentation of several studies evaluating carfilzomib, a selective, next-generation proteasome inhibitor, at the 16th Congress of the European Hematology Association (EHA) Annual Meeting, June 9-12, 2011 in London, UK. "Data being presented this week at EHA continue to demonstrate the strength of clinical evidence for carfilzomib, including the final results from the 005...

2011-06-03 15:00:00

SOUTH SAN FRANCISCO, Calif., June 3, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will present at the Goldman Sachs 32nd Annual Global Healthcare Conference on Wednesday, June 8, 2011 at 1:00 p.m. Eastern Time (10:00 a.m. Pacific Time). Interested parties may access a live webcast of the presentation on our website at: http://www.onyx-pharm.com/investors/event-calendar It is recommended that listeners log on 15 minutes early in order to register...

2011-06-03 12:39:40

Clinical researchers at VCU Massey Cancer Center have successfully completed a Phase I clinical trial evaluating a combination of the drugs Bortezomib and Alvocidib in patients with relapsed or refractory blood cancers, paving the way for a Phase II clinical trial to test the safety and effectiveness of the new therapy. Reported in the journal Clinical Cancer Research, the study determined the maximum tolerated dose with acceptable side effects for this novel drug combination. The trial...

2011-06-02 12:47:00

FRANKLIN LAKES, N.J. and PORTLAND, Ore., June 2, 2011 /PRNewswire/ -- Medco Health Solutions, Inc. (NYSE: MHS) and MolecularMD Corp. today announce the launch of a personalized medicine program for chronic myeloid leukemia (CML) patients. Through this program, Medco will offer patients diagnosed with CML a molecular test known as qRT-PCR (quantitative real-time polymerase chain reaction) BCR-ABL to monitor the disease. (Logo: http://photos.prnewswire.com/prnh/20100609/MEDCOLOGO ) The...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related